Phase II Study of Calcitonin for Tumoral Calcinosis
Completed
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 2
1992-11-01
OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of
calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact
parathyroid hormone levels in patients with tumoral calcinosis.
II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether
hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus.
IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone
metabolism in osteopenic patients with tumoral calcinosis.
Phase II Study of Calcitonin for Tumoral Calcinosis
Completed
National Center for Research Resources (NCRR)
Phase 2
1992-11-01
OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of
calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact
parathyroid hormone levels in patients with tumoral calcinosis.
II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether
hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus.
IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone
metabolism in osteopenic patients with tumoral calcinosis.
Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women
Completed
Novartis
Phase 4
2002-03-01
Calcitonin has been used for many years for treating osteoporosis in postmenopausal women,
and it has been shown that calcitonin reduces pain after spine and hip fracture in women with
osteoporosis. Therefore, this study assesses the safety and efficacy of salmon calcitonin
nasal spray on muscle strength after a forearm fracture, pain, quality of life and fracture
healing in postmenopausal women.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
